Skip to Main Content
For healthcare professionals

Phase Ia first-in-human study of an intravenous STING agonist (BI 1703880) with ezabenlimab in advanced solid tumors (NCT05471856)

 

A Phase Ia, first in human open label dose escalation trial evaluating intravenous STING agonist (BI 1703880) in combination with intravenous ezabenlimab (PD-1 inhibitor) for treatment of advanced solid tumors (NCT05471856)1–3

STING agonist: NCT05471856 (1480-0001)
STING agonist: NCT05471856 (1480-0001)

*For all dose cohorts, the MTD evaluation period is defined as the first 2 cycles of study drug. All cycles are 3 weeks in duration.
DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; MTD, maximum tolerated dose; PD-1, programmed cell death protein-1; PK, pharmacokinetic; STING, stimulator of interferon genes.

References

  1. Doi T, et al. JSMO 2023. Poster e70268.

  2. ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/ct2/show/NCT05471856 (Accessed: February 2026).

  3. Harrington K, et al. Future Oncol 2025;21(2):195–200.